Critical to managing the spread of COVID-19 is the ability to diagnose infection and define
the acquired immune response across the population. While genomic tests for the novel
Several Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) detect the presence of
viral RNA for a limited time frame, when the virus is shed in the upper respiratory tract, tests
able to define exposure and infection beyond this short window of detectable viral
replication are urgently needed. Following infection, antibodies are generated within days …